Background-Hemophilia B (HB) is an inherited bleeding disorder caused by the absence or dysfunction of coagulation factor IX (FIX). A subset of patients who have HB develop neutralizing alloantibodies (inhibitors) against FIX following infusion therapy. HB prevalence and the proportion of patients who develop inhibitors are much lower than that of hemophilia A (HA),
Introduction
Hemophilia is an X-linked inherited bleeding disorder caused by mutations resulting in deficiencies or dysfunctions in coagulation factor (F) VIII (hemophilia A (HA)) or FIX (hemophilia B (HB)). Prevention and treatment of bleeding in patients with hemophilia is accomplished via infusions of recombinant or plasma-derived factor to replace the deficient gene product. A subset of patients undergoing infusion therapy develop neutralizing alloantibodies, termed inhibitors, against the treatment product that nullify the therapeutic efficacy of factor replacement (reviewed in (1)). Inhibitor development complicates patient management (1) (2) (3) and markedly increases patient morbidity and cost of treatment (4) .
Although HA and HB have similar etiologies, inhibitor formation in patients with HB includes some unique features that distinguish it from HA, which include an increased proportion of high responding inhibitors(1), the accompaniment of an anaphylactic response(5-7), decreased success of immune tolerance induction (ITI)(8;9), and a tendency for patients undergoing ITI to develop nephrotic syndrome(9;10). These unique features highlight the need for studies designed to better characterize anti-FIX alloantibody formation in patients with HB.
The gold standard method for laboratory detection of inhibitors in patients with hemophilia is the Nijmegen-Bethesda Assay (NBA), which measures the degree to which patient plasma inhibits the in vitro clotting activity of plasma from a pool of healthy donors following a two hour incubation of patient plasma with normal plasma at 37°C (11) . The Bethesda Unit is defined as the dilution of patient sample required to result in 50% inactivation of factor VIII or FIX in an equivalent volume of normal plasma (e.g. 1 BU is 50% inactivation with no dilution; 100 BU is 50% inactivation following 100-fold dilution). The specificity and reliability of the original Bethesda assay was such that 1.0 BU defined the acceptable limit of positivity. However, with the Nijmegen modification of the BA (buffering the normal plasma with 0.1 M imidazole to pH 7.4) (12) and heat treating test plasmas (13) to destroy residual FVIII or FIX, an assay result of 0.5 or above for FVIII and 0.3 or above for FIX has been suggested to indicate that an inhibitor is present (13) . A lack of consensus creates some ambiguity with regard to the optimal cutoff to define a positive reaction, particularly for FIX inhibitors.
In addition, the specific immune response to FIX is also controversial. Previous studies examining small patient cohorts (n=1-8) have reported that inhibitor positive patients with HB harbor anti-FIX antibodies of IgG 4 subclass which, in some cases, are accompanied by other Ig subclasses (14) (15) (16) (17) (18) (19) (20) . In order to address the paucity of data currently available describing the immune response to FIX, the current cross-sectional study evaluated plasmas from a large group of patients with HB using a fluorescence immunoassay (FLI) in addition to the modified NBA to investigate the relationship between anti-FIX antibody profiles and inhibitor formation.
Materials and Methods

Subjects
Characterization of the anti-FIX antibody profile in NBA-positive HB patient plasmas utilized plasma samples from patients enrolled in the Hemophilia Inhibitor Research Study (HIRS) (21) . Specimens from 12 HB patients that tested ≥ 0.3 NBU were selected from the HIRS study samples. An additional 25 consecutive HIRS HB patient samples that tested < 0.3 NBU were selected as controls (Table 1) . Follow-up FLIs were performed on archived samples from patients of interest identified in initial experiments. The investigational review boards of the Centers for Disease Control and participating sites approved the protocol. All participants or parents of minors gave informed consent. Control samples, which were used to establish the thresholds of positivity used in the FLI, were obtained from 50 paid healthy donors.
Nijmegen-Bethesda assay
Plasma was isolated from citrated blood by two rounds of centrifugation at 1600xg at 4°C for 20 minutes. Processing of blood samples was completed within 2 hours of venipuncture, and plasma samples were shipped to the CDC on cold packs. Functional inhibitor determinations were made using a modified version of the NBA as previously described (13) . Developmental work established a cutoff of 0.3 NBU and above for presence of inhibitory alloantibodies (inhibitor positive) and less than 0.3 NBA for absence of inhibitory alloantibodies (inhibitor negative), based on results from 160 patients using the modified NBA (13) .
Anti-FIX Fluorescence Immunoassay
The anti-FIX FLI is a modified version of our previously described method (22 
Anti-FIX Fluorescence Immunoassay dilution and blocking studies
Plasma samples were diluted 1:30000, 1:3000, and 1:30, and anti-FIX IgG 1-4 , IgA, and IgE binding was measured as described above. Blocking studies to demonstrate the FLI's specificity for anti-FIX antibodies were performed on 1:30 diluted samples by preincubating plasmas with 300μg/ml recombinant FIX or PBS alone for 1 hour prior to incubation with FIX-coupled beads.
Statistics
Statistical analyses were performed on the data presented in Figures 2 and 3 . Differences in categorical data were evaluated using Fisher's exact test. Spearman's correlation coefficient and two-tailed P-values were generated using GraphPad Prism 6 (GraphPad Software, San Diego CA) to assess correlations between FLI and NBA results for samples positive by one or both of the assays. NBA results of 0.0 NBU were converted to 0.01 NBU to allow for plotting on the log scale used in Figure 3 .
Results
Demographics of the 37 HB subjects studied are shown on Table 1 . Twenty-five of the patients were negative and twelve were positive for inhibitor by NBA; 10 of the 12 patients with a positive NBA had a clinical history of an inhibitor reported by the submitting study site. Of the 12 inhibitor patients, 5 were high titer (≥5 NBU) and 7 were low titer (<5 NBU) at the time of testing. All 10 of the inhibitor positive patients with known severities have severe disease, while 25.0%, 58.3%, and 16.7% of inhibitor negative patients have mild, moderate, and severe disease, respectively. The distribution of patients in the categories for exposure days is similar in patients with and without inhibitors. Five of 12 inhibitor patients and 0 of 25 non-inhibitor patients were non-white, although enrollment into HIRS was not population-based, and results may not represent the prevalence of FIX inhibitors overall.
Anti-FIX antibody profiles
A FLI capable of detecting anti-FIX antibodies in plasma diluted up to 1:30000 in a manner that is blocked by the by the addition of excess uncoupled FIX (Figure 1 ), was used to characterize anti-FIX antibody profiles in plasma samples from 37 patients with HB and 50 healthy controls. Figure 2 and Table 2 report anti-FIX FLI results by Ig subclass for individual plasma samples from healthy donors (control) and from patients with HB segregated into two categories corresponding to NBA-negative (<0.3 NBU; n=25) and NBApositive (≥ 0.3 NBU; n=12) based on a method-specific cutoff established for the modified NBA (13) . A small proportion of the 25 NBA-negative samples were positive for anti-FIX IgG 1 , IgG 4 , IgA, or IgE (n= 0-3, 0-12%), but these samples demonstrated no significant difference in antibody frequency compared to that of healthy donors. A slightly higher proportion of NBA-negative samples were positive for IgG 2 (n=5, 20%; P=0.0375). All twelve NBA-positive samples tested positive for anti-FIX IgG 4 . IgG 1 and IgG 2 were detected in ten (83%) of the NBA-positive samples, and IgG 3 , IgA, and IgE were positive in 58%, 67% and 75%, respectively. FLI rates of positivity were significantly higher on NBApositive samples compared to both the healthy controls (P<0.0001) and NBA-negative HB samples (P<0.002) for all Igs tested.
Correlation of anti-FIX subclass specific FLI results with NBA titers
In order to examine the link between anti-FIX antibody titers reported by the FLI and FIXspecific inhibition of in vitro clotting reported by the NBA, linear correlations were calculated according to Spearman on samples positive by one or both of the assays. FLI levels for anti-FIX IgG 4 demonstrated a strong positive correlation with the NBA (r=0.8222; P=.0003; Figure 3 , Table 2 ), while correlations were significant, yet more moderate for anti-FIX IgG 1 , IgG 2 , and IgA ( Figure 3 , Table 2 ). FLI results for IgG 3 and IgE did not have significant correlations with the NBA. NBA-positive samples from patients 1 (0.3 NBU) and 3 (0.4 NBU), which had inhibitor titers close to the 0.3 NBU cut-off for positivity established in our previous study (13) , were positive for anti-FIX IgG 4 , for which both samples tested slightly higher than the FLI's threshold for positivity (Table 3A) , but were negative for other anti-FIX Igs. In contrast, a sample from patient 2, which also tested at the threshold for positivity of the NBA (0.3 NBU), was strongly positive by FLI for anti-FIX IgG [1] [2] [3] [4] . All specimens with ≥0.3 NBU were positive for IgG 4 .
Serial Specimens
A subset of samples in the current study had detectable anti-FIX antibodies by FLI, but functional inhibition was not observed using the NBA (Table 3B) . We and others have previously demonstrated that this phenomenon also occurs in a small percentage of samples from patients with HA (22) (23) (24) (25) and may result from the presence of antibodies that are of low titer, low affinity, or directed against low-impact epitopes. In order to gain insight into the dynamics of antibody production in these patients, FLIs were performed on archived serial draws (when available) from NBA-negative patients who tested positive for one or more anti-FIX Igs in the original analysis (Table 3 ; NBA results for initial study samples are marked with an *). One patient (patient 15) was negative for all anti-FIX Igs tested on serial samples drawn after his original study specimen, while the other seven patients who had archived samples available for analysis, despite remaining NBA negative, had repeat positive results for one or more anti-FIX antibodies using serial draws (patients 16-22, Table 3B ). FLI results for patient 18 report the presence of anti-FIX IgG 1 and IgG 4 in four samples taken over a period of more than 4 years. This antibody profile correlates well with functional inhibition of FIX (current study) and FVIII (22;24) , yet this patient never tested positive by NBA over that time span.
As a means for comparison, Table 3A reports FLI data for all NBA-positive patient samples as well as any available archived serial samples from those patients (patients 1-12). Patient 3 is of interest due the presence of a low titer positive anti-FIX IgG 4 that was detected by FLI in six study samples drawn over a period of more than 5 years (Table 3A) . Notably, only one of these samples tested positive by the NBA (0.4 NBU), while the other five were negative. These results may be an indication that the patient's low titer IgG 4 , which was only slightly above the level of detection by FLI, may be hovering at or just below the NBA detection threshold. Raw FLI data for patient samples that were negative by the NBA and for all subclasses of anti-FIX Igs are shown in Table 4 .
Discussion
The current study describes a method for direct detection of anti-FIX antibodies in patients who have HB. The data presented here demonstrate that the described method is capable of detecting antibodies in plasma diluted up to 1:30000, there is a strong positive correlation between plasma levels of anti-FIX IgG 4 and NBA results, and samples with NBA results as low as 0.3 NBU were positive for anti-FIX IgG 4 .
The prevalence of inhibitors among all patients with HB and HA has been reported at 1.5% and 5-7%, respectively, a difference that is amplified when comparing patients with a severe form of their disease, in which 3.8% and 30% of HB and HA patients develop inhibitors, respectively (26) (27) (28) . The lower relative frequency of neutralizing antibody formation in patients with HB compared to HA is hypothesized to result in part from three important distinguishing features of the disorders. First, there is a high degree of homology between FIX and other vitamin K-dependent clotting factors which may confer some tolerance to FIX in patients with no circulating FIX (29) , a condition that is not true of FVIII. Second, there is a lower proportion of patients with HB who fall into the severe category (severe HB (30-40%) relative to patients with HA (60%) (30) , and patients with undetectable plasma clotting factor are more likely to develop an inhibitory antibody response to replacement therapy. Third, patients with severe HB are three times more likely than those with severe HA to have a missense mutation (47% vs 16%) and thus a gene product (31) , and the physiologic plasma concentration of FIX (0.1-0.2 micrograms/mL) far exceeds that of FVIII (3-5 micrograms/mL). These factors combine to result in patients with HB having, on average, more gene product and higher levels of circulating cross reactive material (CRM) to their treatment product relative to patients with HA who are more likely to have a null mutation (1) . Notably, all of the patients in the current study who have positive NBA results have severe HB caused by nonsense or large deletion mutations, and only 2 of 14 (14.3%) patients who tested negative by the NBA and for all classes of ant-FIX Igs had severe HB. These data highlight the importance of disease severity and mutation type as indicators for risk of inhibitor development in patients who have HB. mechanism responsible for anaphylaxis in patients with HB is unclear, but the high standard dose used for FIX infusions, which is required to achieve adequate plasma concentrations for hemostasis, has been hypothesized to play a role (29) . Antigen exposure may lead to anaphylaxis if the dose is sufficient to overwhelm the binding capacity of IgG blocking antibodies(32;33), which share antigen specificity with IgE bound to FcεRI on mast cells, thus allowing for mast cell activation (reviewed in (34)). Alternatively, studies using mouse models suggest that IgG-immune-complex activation of FcγRIII may induce anaphylaxis via activation of macrophage, mast cells, or neutrophils (33-37).
Data reported here and previously on both HB (14) (15) (16) (17) (18) (19) (20) and HA (22;24) argue that the presence of a product-reactive IgG 4 is the best predictor of a functional inhibitor. A notable exception to this rule is patient 18 in the current study, who tested positive for anti-FIX IgG 4 four times over a four-years while remaining NBA-negative. The discordance of patient 18's FLI and NBA results is potentially due to 1) the presence of an antibody pre-bound to a target that has FIX binding affinity, thus allowing for indirect capture of antibodies 2) the presence of sufficient levels of FIX CRM in the patient's plasma to act as an anti-FIX reservoir capable of out-competing the NBA assay target, but insufficient to saturate assay targets in the FLI, a possibility supported by previous studies that reported circulating FIX immune complexes in patients with HB (38), or 3) the possibility that the composition of the patient's anti-FIX antibody profile, despite containing significant amounts IgG 1 and IgG 4, may lack the affinity and/or epitope localization required to impose functional inhibition detectable by the NBA. A method-specific cutoff was established for the modified NBA used in this study based on assay results from 160 patients (13) . The observation that samples in the 0.3-0.4 NBU range in the current study have detectable anti-FIX IgG 4 antibodies, which are likely responsible for the trace amount of neutralizing activity reported by the NBA, highlights the need for standardization of inhibitor detection methods because many clinical laboratories place the cutoff for positivity at or above 0.5 NBU and likely miss low level inhibitors. While one or more classes of anti-FIX antibodies were present in 40% (10 of 25) of patient samples that were negative by the NBA, IgG 4 was present in only 3 (12%). Studies show that inhibitor formation occurs in only 1.5% of patients with HB(27); thus, it follows that the majority of the patients who have non-neutralizing anti-FIX antibodies will not convert from NBA-negative to NBA-positive. More clinical data are needed to support this hypothesis, which differs from HA, in that a higher proportion of HA patients develop inhibitors, with evidence that anti-FVIII IgG 1 may be predictive of future inhibitor development (22) .
Data presented in the current study demonstrate the relevance of anti-FIX IgG 4 antibodies, as determined by FLI, to functional FIX inhibitors. Given that some FIX patients have NBA results in the borderline or indeterminate range, the FLI assay can be helpful in clinical studies and potentially in clinical care of HB patients to better detect, interpret and manage patients with low titer FIX inhibitors. The current study is limited in that it is cross-sectional, not optimally age/race matched for cases and controls, and has a small sample size. Additionally, although the study provides strong empirical evidence to support the above conclusions, it is limited in that does not identify the underlying factors that contribute to IgG 4 development in some patients and not others, and it remains unclear why the presence of IgG 4 plays such an important role in functional inhibition of FIX. A recent study by Hofbauer et al. characterizing neutralizing versus non-neutralizing antibodies in patients with hemophilia A, showed that anti-FVIII IgG 4 was found exclusively in samples from patients who were NBA positive. In addition, these authors showed that patients who had inhibitors had anti-FVIII antibodies with affinities up to 100-fold higher than patients who were inhibitor negative and that anti-FVIII IgG 4 antibodies had the highest affinity of all anti-FVIII subclasses. Hofbauer et al. (25) hypothesize that these high affinity antibodies are responsible for neutralizing FVIII activity (25) . A similar mechanism may be involved in inhibition of FIX in patients who have HB. Future studies designed to monitor HB patient anti-FIX antibody profiles prospectively are required to better characterize the factors that contribute to the initiation and evolution of anti-FIX antibody production and to assess the prognostic value of anti-FIX antibody profiles as they relate to FIX neutralization.
Essentials
•
Studies characterizing neutralizing antibodies (inhibitors) in hemophilia B (HB) are lacking.
• The current study describes anti-factor (F) IX antibody profiles in 37 patients who have HB.
• Anti-FIX IgG4 levels exhibited a strong positive correlation with Nijmegen-Bethesda results.
• These data will help to more clearly define, predict, and treat alloantibody formation in HB. Demographics of HB subjects Table 2 Summary of fluorescence immunoassay results (FLI) for anti-factor IX antibodies segregated by class and IgG subclass 2 (4) 1 (2) 2 (4) 3 (6) 2 (4) HB specimens <0. (12) 3 (12) 3 (12) HB specimens ≥0. Table 3 Raw data for patients who tested positive for one or more anti-factor IX immunoglobulins by fluorescence immunoassay. Positive results in bold.
Patient Severity History of inhibitor
F9 mutation (type)
Exposure days † Interval days since first draw Table 4 Raw data for patients who tested negative by the Nijmegen Bethesda Assay and for all anti-factor IX immunoglobulins by the anti-Factor IX fluorescence immunoassay. Table 2 ; † Exposure days at study enrollment.
Patient Severity History of inhibitor
